RxSight (RXST)
NASDAQ:RXST
RXST Stock Chart & Stats
$6.83
-$1.16(-3.26%)
At close: 4:00 PM EST
$6.83
-$1.16(-3.26%)
Day’s Range― - ―
52-Week Range$5.90 - $16.74
Previous CloseN/A
Volume110.15K
Average Volume (3M)733.37K
Market Cap
$281.85M
Enterprise Value$272.94M
Total Cash (Recent Filing)$228.13M
Total Debt (Recent Filing)$11.04M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 12, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding41,266,335
10 Day Avg. Volume818,687
30 Day Avg. Volume733,366
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)1.56
Price to Sales (P/S)3.19
P/FCF Ratio-22.18
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit2.65
Enterprise Value/Ebitda-6.88
Forecast
1Y Price Target
$10.33Price Target Upside51.24% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$130.97M
Bulls Say, Bears Say
Bulls Say
Commercial ExecutionCommercial initiatives and enhanced clinical support are improving procedure utilization and could drive revenue recovery as more surgeons adopt the adjustable lens workflow.
Financial LeadershipAppointment of a seasoned chief financial officer with major medical device experience enhances financial planning and supports issuance of more achievable, bottoms-up guidance that can improve investor confidence.
Installed Base ExpansionMeaningful expansion of the installed base in the premium intraocular lens segment strengthens the addressable market and supports recurring device and lens sales as utilization rises.
Bears Say
Customer Acquisition RiskManagement's decision to prioritize support and onboarding for existing customers over new account acquisition risks slowing new placements and ceding share to competitors launching alternative lenses.
Margin PressureLower production volumes and the resulting higher-cost inventory flow are expected to raise per-unit manufacturing costs and compress gross margins, pressuring profitability.
Visibility And Guidance RiskWithholding forward financial guidance during the CFO transition reduces near-term visibility and is likely to keep analysts cautious until clear operational proof points are available.
RxSight News
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $5.90 and its highest was $16.74 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $281.85M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is May 12, 2026 which is in 29 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Feb 25, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.115.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.31.
How many shares outstanding does RxSight have?
RxSight has 41,266,335 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went down -10.102%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.33 (51.24% Upside)
$10.33 (51.24% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 577.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.86%
12-Months-Change
Fundamentals
Return on Equity
-14.05%
Trailing 12-Months
Asset Growth
-2.20%
Trailing 12-Months
Company Description
RxSight
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: notable operational and clinical strengths (strong LAL margins, improving sequential LAL volumes, compelling clinical evidence, a growing installed base and a robust cash position) but also material near-term headwinds (large LDD revenue decline, a wider GAAP loss, manufacturing-driven margin pressure and conservative 2026 guidance). Management emphasized early signs of commercial improvement and a measured plan to drive utilization and international expansion, while remaining prudent in 2026 assumptions.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$10.33
▲(51.24% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Butterfly Network
―
NeuroPace
―
Ceribell, Inc.
―
Ownership Overview
5.65% Insiders
13.76% Mutual Funds
23.03% Other Institutional Investors
43.06% Public Companies and
Individual Investors